UNITY Biotechnology (UBX) announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema. As reported in the article titled, “Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema,” the results suggested that the selective clearance of senescent cells in the retina provided disease-modifying and long-lasting improvements in vision in patients with DME, supporting the potential of UBX1325 as a novel modality for retinal diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX:
- Buy Rating for Unity Biotechnology’s UBX1325: Promising Phase 2b ASPIRE Trial Data and Novel Senolytic Mechanism in DME Treatment
- Unity Biotechnology reports Q1 EPS (43c), consensus (40c)
- Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
- Unity Biotechnology price target lowered to $4 from $6 at Chardan
- Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study